MPG.eBooks - Search Results - "Transport"

Cover Image

1

Pharmacoeconomic review report: Empagliflozin (Jardiance)

Published 2015

CADTH

Subjects: “...Sodium-Glucose Transporter 2 Inhibitors / therapeutic use...”

Cover Image

2

Pharmacoeconomic review report: Empagliflozin (Jardiance)

Published 2015

CADTH

Subjects: “...Sodium-Glucose Transporter 2 Inhibitors / therapeutic use...”

Cover Image

3

Cardiovascular outcomes with sodium-glucose co-transporter 2 inhibitors : a review of the clinical evidence

Published 2015

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Sodium-Glucose Transporter 2 Inhibitors...”

Cover Image

4

CADTH Canadian Drug Expert Committee final recommendation: Empagliflozin / metformin hydrochloride (Synjardy -- Boehringer Ingelheim Canada Ltd.) : indication : type 2 diabetes mel...

Published 2016

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Sodium-Glucose Transporter 2 Inhibitors / therapeutic use...”

Cover Image

5

Clinical review report: Ertugliflozin (Steglatro) (Merck Canada Inc.) : indication : type 2 diabetes mellitus

Published 2019

CADTH

Subjects: “...Sodium-Glucose Transporter 2 Inhibitors / therapeutic use...”

Cover Image

6

Pharmacoeconomic review report: Ertugliflozin (Steglatro) (Merck Canada Inc.) : indication : type 2 diabetes mellitus

Published 2019

CADTH

Subjects: “...Sodium-Glucose Transporter 2 Inhibitors / therapeutic use...”

Cover Image

7

Pharmacoeconomic review report: Ertugliflozin (Steglatro) (Merck Canada Inc.) : indication : type 2 diabetes mellitus

Published 2019

CADTH

Subjects: “...Sodium-Glucose Transporter 2 Inhibitors / therapeutic use...”

Cover Image

8

Sodium-glucose cotransporter 2 inhibitors for the treatment of diabetic nephropathy : a review of clinical effectiveness

by Banerjee, Srabani, Grobelna, Aleksandra
Published 2019

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Sodium-Glucose Transporter 2 Inhibitors / therapeutic use...”

Cover Image

9

Pharmacoeconomic review report: Empagliflozin and Metformin fixed-dose combination (Synjardy)

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Sodium-Glucose Transporter 2 Inhibitors...”

Cover Image

10

Clinical review report: Dapagliflozin (Forxiga)

Published 2016

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Sodium-Glucose Transporter 2 Inhibitors...”

Cover Image

11

Common drug review new combination product: Ertugliflozin/Metformin fixed-dose combination (Segluromet) Merck Canada Inc. : indication : type 2 diabetes mellitus

Published 2019

CADTH

Subjects: “...Sodium-Glucose Transporter 2 Inhibitors / therapeutic use...”

Cover Image

12

Empagliflozin (Jardiance)

Published 2015

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Sodium-Glucose Transporter 2 Inhibitors / therapeutic use...”

Cover Image

13

Sodium-glucose co-transporter 2 inhibitors for the treatment of type 2 diabetes : a review of clinical effectiveness, cost-effectiveness, and guidelines

by Amanda, Shane, Butcher, Robyn
Published 2019

CADTH

Subjects: “...Sodium-Glucose Transporter 2 Inhibitors / therapeutic use...”

Cover Image

14

CADTH CDEC final recommendation: Empagliflozin (Jardiance -- Boehringer Ingelheim (Canada) Ltd.) : indication : Type 2 Diabetes mellitus

Published 2015

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Sodium-Glucose Transporter 2 Inhibitors / therapeutic use...”

Cover Image

15

Patient group input submissions: Empagliflozin and metformin (Synjardy) for diabetes mellitus (Type 2)

Published 2017

CADTH

Subjects: “...Sodium-Glucose Transporter 2 Inhibitors / therapeutic use...”